Gastric neuroendocrine neoplasms.
Journal
Nature reviews. Disease primers
ISSN: 2056-676X
Titre abrégé: Nat Rev Dis Primers
Pays: England
ID NLM: 101672103
Informations de publication
Date de publication:
11 Apr 2024
11 Apr 2024
Historique:
accepted:
27
02
2024
medline:
12
4
2024
pubmed:
12
4
2024
entrez:
11
4
2024
Statut:
epublish
Résumé
Gastric neuroendocrine neoplasms (gNENs) display peculiar site-specific features among all NENs. Their incidence and prevalence have been rising in the past few decades. gNENs comprise gastric neuroendocrine carcinomas (gNECs) and gastric neuroendocrine tumours (gNETs), the latter further classified into three types. Type I anatype II gNETs are gastrin-dependent and develop in chronic atrophic gastritis and as part of Zollinger-Ellison syndrome within a multiple endocrine neoplasia type 1 syndrome (MEN1), respectively. Type III or sporadic gNETs develop in the absence of hypergastrinaemia and in the context of a near-normal or inflamed gastric mucosa. gNECs can also develop in the context of variable atrophic, relatively normal or inflamed gastric mucosa. Each gNEN type has different clinical characteristics and requires a different multidisciplinary approach in expert dedicated centres. Type I gNETs are managed mainly by endoscopy or surgery, whereas the treatment of type II gNETs largely depends on the management of the concomitant MEN1. Type III gNETs may require both locoregional approaches and systemic treatments; NECs are often metastatic and therefore require systemic treatment. Specific data regarding the systemic treatment of gNENs are lacking and are derived from the treatment of intestinal NETs and NECs. An enhanced understanding of molecular and clinical pathophysiology is needed to improve the management and outcomes of patients' gNETs.
Identifiants
pubmed: 38605021
doi: 10.1038/s41572-024-00508-y
pii: 10.1038/s41572-024-00508-y
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
25Informations de copyright
© 2024. Springer Nature Limited.
Références
WHO Classification of Tumours Editorial Board. WHO Classification of Endocrine and Neuroendocrine Tumours (WHO, 2022).
WHO Classification of Tumours Editorial Board. WHO Classification of Digestive Tumours (WHO, 2019).
Rindi, G. et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr. Pathol. 33, 115–154 (2022).
pubmed: 35294740
doi: 10.1007/s12022-022-09708-2
Raj, N. et al. Real-time genomic characterization of metastatic pancreatic neuroendocrine tumors has prognostic implications and identifies potential germline actionability. JCO Precis. Oncol. 2018, PO.17.00267 (2018).
pubmed: 30687805
Rindi, G., Luinetti, O., Cornaggia, M., Capella, C. & Solcia, E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 104, 994–1006 (1993).
pubmed: 7681798
doi: 10.1016/0016-5085(93)90266-F
Rindi, G. et al. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J. Surg. 20, 168–172 (1996).
pubmed: 8661813
doi: 10.1007/s002689900026
Rindi, G. et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 116, 532–542 (1999).
pubmed: 10029611
doi: 10.1016/S0016-5085(99)70174-5
Vanoli, A. et al. Prognostic evaluations tailored to specific gastric neuroendocrine neoplasms: analysis of 200 cases with extended follow-up. Neuroendocrinology 107, 114–126 (2018).
pubmed: 29895024
doi: 10.1159/000489902
Dasari, A. et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 3, 1335–1342 (2017). This is the largest population-based study report to date to highlight epidemiology of neuroendocrine tumours, including those of the stomach.
pubmed: 28448665
pmcid: 5824320
doi: 10.1001/jamaoncol.2017.0589
Rustgi, S. D. et al. Epidemiology of gastric malignancies 2000–2018 according to histology: a population-based analysis of incidence and temporal trends. Clin. Gastroenterol. Hepatol. 21, 3285–3295.e8 (2023).
pubmed: 36792000
doi: 10.1016/j.cgh.2023.01.037
IARC. Cancer Today stomach cancer data. WHO https://gco.iarc.fr/today/en/dataviz/tables?mode=population&cancers=7 (2022).
Ellis, L., Shale, M. J. & Coleman, M. P. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am. J. Gastroenterol. 105, 2563–2569 (2010).
pubmed: 20823835
doi: 10.1038/ajg.2010.341
Carmack, S. W., Genta, R. M., Schuler, C. M. & Saboorian, M. H. The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. Am. J. Gastroenterol. 104, 1524–1532 (2009).
pubmed: 19491866
doi: 10.1038/ajg.2009.139
Vannella, L. et al. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment. Pharmacol. Ther. 33, 1361–1369 (2011).
pubmed: 21492197
doi: 10.1111/j.1365-2036.2011.04659.x
Shah, S. C., Piazuelo, M. B., Kuipers, E. J. & Li, D. AGA clinical practice update on the diagnosis and management of atrophic gastritis: expert review. Gastroenterology 161, 1325–1332.e7 (2021).
pubmed: 34454714
doi: 10.1053/j.gastro.2021.06.078
Garcia-Carbonero, R. et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann. Oncol. 21, 1794–1803 (2010).
pubmed: 20139156
doi: 10.1093/annonc/mdq022
Genus, T. S. E. et al. Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015. Br. J. Cancer 121, 966–972 (2019).
pubmed: 31649320
pmcid: 6889414
doi: 10.1038/s41416-019-0606-3
Palepu, J. et al. Trends in diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in India: a report of multicenter data from a web-based registry. Indian. J. Gastroenterol. 36, 445–451 (2017).
pubmed: 29457213
doi: 10.1007/s12664-017-0808-7
Fan, J.-H. et al. A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china. Oncotarget 8, 71699–71708 (2017).
pubmed: 29069739
pmcid: 5641082
doi: 10.18632/oncotarget.17599
Tsai, H.-J. et al. The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study. PLoS ONE 8, e62487 (2013).
pubmed: 23614051
pmcid: 3632554
doi: 10.1371/journal.pone.0062487
Masui, T., Ito, T., Komoto, I. & Uemoto, S. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study. BMC Cancer 20, 1104 (2020).
pubmed: 33189127
pmcid: 7666508
doi: 10.1186/s12885-020-07581-y
Eom, B. W., Jung, K.-W., Won, Y.-J., Yang, H. & Kim, Y.-W. Trends in gastric cancer incidence according to the clinicopathological characteristics in Korea, 1999–2014. Cancer Res. Treat. 50, 1343–1350 (2018).
pubmed: 29361823
pmcid: 6192902
doi: 10.4143/crt.2017.464
Lahner, E. et al. Gastric cancer in patients with type I gastric carcinoids. Gastric Cancer 18, 564–570 (2015).
pubmed: 24890255
doi: 10.1007/s10120-014-0393-8
Lenti, M. V. et al. Autoimmune gastritis. Nat. Rev. Dis. Prim. 6, 56 (2020).
pubmed: 32647173
doi: 10.1038/s41572-020-0187-8
Vannella, L., Lahner, E., Osborn, J. & Annibale, B. Systematic review: gastric cancer incidence in pernicious anaemia. Aliment. Pharmacol. Ther. 37, 375–382 (2013).
pubmed: 23216458
doi: 10.1111/apt.12177
Miceli, E. et al. Long-term natural history of autoimmune gastritis: results from a prospective, monocentric series. Am. J. Gastroenterol. https://doi.org/10.14309/ajg.0000000000002619 (2023).
Panzuto, F. et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1–G3. J. Neuroendocrinol. 35, e13306 (2023). This paper discusses the guidelines of the European Neuroendocrine Tumor Society (ENETS) regarding the clinical management of gastric neuroendocrine tumours.
pubmed: 37401795
doi: 10.1111/jne.13306
Yao, J. C. et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26, 3063–3072 (2008).
pubmed: 18565894
doi: 10.1200/JCO.2007.15.4377
Panzuto, F. et al. Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: a multicentre retrospective study. Dig. Liver Dis. 51, 1456–1460 (2019). This is a large multicentre retrospective study to evaluate prognostic factors in gastric neuroendocrine tumours.
pubmed: 31175013
doi: 10.1016/j.dld.2019.04.016
Felder, S. et al. Gastric neuroendocrine neoplasias: manifestations and comparative outcomes. Endocr. Relat. Cancer 26, 751–763 (2019).
pubmed: 31272081
pmcid: 6686747
doi: 10.1530/ERC-18-0582
Exarchou, K., Howes, N. & Pritchard, D. M. Systematic review: management of localised low‐grade upper gastrointestinal neuroendocrine tumours. Aliment. Pharmacol. Ther. 51, 1247–1267 (2020).
pubmed: 32390152
doi: 10.1111/apt.15765
Laffi, A. et al. Gastric neuroendocrine tumors (g-NETs): a systematic review of the management and outcomes of type 3 g-NETs. Cancers 15, 2202 (2023).
pubmed: 37190131
pmcid: 10137004
doi: 10.3390/cancers15082202
Min, B.-H. et al. Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours. Br. J. Surg. 105, 1480–1486 (2018).
pubmed: 29893418
doi: 10.1002/bjs.10901
Engevik, A. C., Kaji, I. & Goldenring, J. R. The physiology of the gastric parietal cell. Physiol. Rev. 100, 573–602 (2020). This is a paper on the state-of-the-art knowledge about gastric physiology, which is fundamental to understand pathogenesis and management of type I and type II gNETs.
pubmed: 31670611
doi: 10.1152/physrev.00016.2019
Jensen, R. T. & Ito, T. in Endotext (eds Feingold, K. et al.) (Endotext, 2023).
Amedei, A. et al. Molecular mimicry between Helicobacter pylori antigens and H
pubmed: 14568977
pmcid: 2194239
doi: 10.1084/jem.20030530
Lundell, L., Vieth, M., Gibson, F., Nagy, P. & Kahrilas, P. J. Systematic review: the effects of long‐term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment. Pharmacol. Ther. 42, 649–663 (2015).
pubmed: 26177572
doi: 10.1111/apt.13324
Vanoli, A., Parente, P., Fassan, M., Mastracci, L. & Grillo, F. Gut inflammation and tumorigenesis: every site has a different tale to tell. Intern. Emerg. Med. 18, 2169–2179 (2023).
pubmed: 37249755
pmcid: 10635962
doi: 10.1007/s11739-023-03320-w
Arnold, R. et al. Antral gastrin-producing G-cells and somatostatin-producing D-cells in different states of gastric acid secretion. Gut 23, 285–291 (1982).
pubmed: 6122629
pmcid: 1419730
doi: 10.1136/gut.23.4.285
Annibale, B. et al. Antral gastrin cell hyperfunction and Helicobacter pylori infection. Aliment. Pharmacol. Ther. 10, 607–615 (1996).
pubmed: 8853766
doi: 10.1046/j.1365-2036.1996.31173000.x
Rindi, G. et al. Helicobacter pylori infection in children with antral gastrin cell hyperfunction. J. Pediatr. Gastroenterol. Nutr. 18, 152–158 (1994).
pubmed: 7912267
Pashankar, D. S., Israel, D. M., Jevon, G. P. & Buchan, A. M. J. Effect of long-term omeprazole treatment on antral G and D cells in children. J. Pediatr. Gastroenterol. Nutr. 33, 537–542 (2001).
pubmed: 11740225
Solcia, E. et al. Gastric carcinoids and related endocrine growths. Digestion 35, 3–22 (1986).
pubmed: 3539679
doi: 10.1159/000199378
Rindi, G. & Solcia, E. Endocrine hyperplasia and dysplasia in the pathogenesis of gastrointestinal and pancreatic endocrine tumors. Gastroenterol. Clin. North. Am. 36, 851–865 (2007).
pubmed: 17996794
doi: 10.1016/j.gtc.2007.08.006
Solcia, E. et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 41, 185–200 (1988).
pubmed: 3072229
doi: 10.1159/000199786
Calvete, O. et al. Exome sequencing identifies ATP4A gene as responsible of an atypical familial type I gastric neuroendocrine tumour. Hum. Mol. Genet. 24, 2914–2922 (2015).
pubmed: 25678551
doi: 10.1093/hmg/ddv054
Calvete, O. et al. A knockin mouse model for human ATP4a R703C mutation identified in familial gastric neuroendocrine tumors recapitulates the premalignant condition of the human disease and suggests new therapeutic strategies. Dis. Model. Mech. 9, 975–984 (2016).
pubmed: 27491072
pmcid: 5047686
Langhans, N. et al. Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. Gastroenterology 112, 280–286 (1997).
pubmed: 8978369
doi: 10.1016/S0016-5085(97)90000-7
Benítez, J., Marra, R., Reyes, J. & Calvete, O. A genetic origin for acid–base imbalance triggers the mitochondrial damage that explains the autoimmune response and drives to gastric neuroendocrine tumours. Gastric Cancer 23, 52–63 (2020).
pubmed: 31250150
doi: 10.1007/s10120-019-00982-4
Furlan, D. et al. Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract. Clin. Cancer Res. 10, 947–957 (2004).
pubmed: 14871972
doi: 10.1158/1078-0432.CCR-1068-3
D’Adda, T., Keller, G., Bordi, C. & Höfler, H. Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. Lab. Invest. 79, 671–677 (1999).
pubmed: 10378509
Toliat, M. R., Berger, W., Ropers, H. H., Neuhaus, P. & Wiedenmann, B. Mutations in the MEN I gene in sporadic neuroendocrine tumours of gastroenteropancreatic system. Lancet 350, 1223 (1997).
pubmed: 9652567
doi: 10.1016/S0140-6736(05)63453-8
Bordi, C. Neuroendocrine pathology of the stomach: the Parma contribution. Endocr. Pathol. 25, 171–180 (2014).
pubmed: 24782101
doi: 10.1007/s12022-014-9315-x
Chatzipanagiotou, O. et al. All you need to know about gastrinoma today | Gastrinoma and Zollinger-Ellison syndrome: a thorough update. J. Neuroendocrinol. 35, e13267 (2023).
pubmed: 37042078
doi: 10.1111/jne.13267
Debelenko, L. V. et al. The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type II gastric carcinoids. Gastroenterology 113, 773–781 (1997).
pubmed: 9287968
doi: 10.1016/S0016-5085(97)70171-9
Trinh, V. Q., Shi, C. & Ma, C. Gastric neuroendocrine tumours from long‐term proton pump inhibitor users are indolent tumours with good prognosis. Histopathology 77, 865–876 (2020).
pubmed: 32702178
doi: 10.1111/his.14220
Abraham, S. C., Carney, J. A., Ooi, A., Choti, M. A. & Argani, P. Achlorhydria, parietal cell hyperplasia, and multiple gastric carcinoids. Am. J. Surgical Pathol. 29, 969–975 (2005).
doi: 10.1097/01.pas.0000163363.86099.9f
Ooi, A. et al. An unusual case of multiple gastric carcinoids associated with diffuse endocrine cell hyperplasia and parietal cell hypertrophy. Endocr. Pathol. 6, 229–237 (1995).
pubmed: 12114744
doi: 10.1007/BF02739887
WHO Classification of Tumours Editorial Board. WHO Classification of Tumours: Digestive System Tumours 5th edn, Vol. 1 (WHO, 2019).
Venizelos, A. et al. Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms. Endocr. Relat. Cancer 30, e230057 (2023).
pubmed: 37410378
doi: 10.1530/ERC-23-0057
Taboada, R. et al. Clinicopathological and molecular profile of grade 3 gastroenteropancreatic neuroendocrine neoplasms. J. Neuroendocrinol. 34, e13099 (2022).
pubmed: 35174558
doi: 10.1111/jne.13099
Yachida, S. et al. Comprehensive genomic profiling of neuroendocrine carcinomas of the gastrointestinal system. Cancer Discov. 12, 692–711 (2022).
pubmed: 34880079
pmcid: 9394397
doi: 10.1158/2159-8290.CD-21-0669
Carabotti, M. et al. Upper gastrointestinal symptoms in autoimmune gastritis: a cross-sectional study. Medicine 96, e5784 (2017).
pubmed: 28072728
pmcid: 5228688
doi: 10.1097/MD.0000000000005784
Lenti, M. V. et al. Cell blood count alterations and patterns of anaemia in autoimmune atrophic gastritis at diagnosis: a multicentre study. J. Clin. Med. 8, 1992 (2019).
pubmed: 31731715
pmcid: 6912578
doi: 10.3390/jcm8111992
Cellini, M. et al. Hashimoto’s thyroiditis and autoimmune gastritis. Front. Endocrinol. 8, 92 (2017).
doi: 10.3389/fendo.2017.00092
Kalkan, Ç. & Soykan, I. Polyautoimmunity in autoimmune gastritis. Eur. J. Intern. Med. 31, 79–83 (2016).
pubmed: 27085391
doi: 10.1016/j.ejim.2016.03.025
Zelissen, P. M., Bast, E. J. & Croughs, R. J. Associated autoimmunity in Addison’s disease. J. Autoimmun. 8, 121–30 (1995).
pubmed: 7734032
doi: 10.1006/jaut.1995.0009
Dixon, M. F., Genta, R. M., Yardley, J. H. & Correa, P. Classification and grading of gastritis. Am. J. Surg. Pathol. 20, 1161–1181 (1996).
pubmed: 8827022
doi: 10.1097/00000478-199610000-00001
Conti, L. et al. Seronegative autoimmune atrophic gastritis is more common in elderly patients. Dig. Liver Dis. 52, 1310–1314 (2020).
pubmed: 32487505
doi: 10.1016/j.dld.2020.04.015
Hershko, C. et al. Variable hematologic presentation of autoimmune gastritis: age-related progression from iron deficiency to cobalamin depletion. Blood 107, 1673–1679 (2006).
pubmed: 16239424
doi: 10.1182/blood-2005-09-3534
Lehy, T., Cadiot, G., Mignon, M., Ruszniewski, P. & Bonfils, S. Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 33, 1275–1279 (1992).
pubmed: 1358767
pmcid: 1379501
doi: 10.1136/gut.33.9.1275
Berna, M. J. et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J. Clin. Endocrinol. Metab. 93, 1582–1591 (2008).
pubmed: 18270260
pmcid: 2386679
doi: 10.1210/jc.2007-2279
Roy, P. K. et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine 79, 379–411 (2000).
pubmed: 11144036
doi: 10.1097/00005792-200011000-00004
Ito, T., Cadiot, G. & Jensen, R. T. Diagnosis of Zollinger-Ellison syndrome: increasingly difficult. World J. Gastroenterol. 18, 5495–5503 (2012).
pubmed: 23112541
pmcid: 3482635
doi: 10.3748/wjg.v18.i39.5495
Metz, D. C., Cadiot, G., Poitras, P., Ito, T. & Jensen, R. T. Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing. Int. J. Endocr. Oncol. 4, 167–185 (2017).
pubmed: 29326808
pmcid: 5757869
doi: 10.2217/ije-2017-0018
Berna, M. J., Hoffmann, K. M., Serrano, J., Gibril, F. & Jensen, R. T. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine 85, 295–330 (2006).
pubmed: 17108778
doi: 10.1097/01.md.0000236956.74128.76
Modlin, I. M. et al. Chromogranin A—biological function and clinical utility in neuro endocrine tumor disease. Ann. Surg. Oncol. 17, 2427–2443 (2010).
pubmed: 20217257
doi: 10.1245/s10434-010-1006-3
Pimentel-Nunes, P. et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 51, 365–388 (2019).
pubmed: 30841008
doi: 10.1055/a-0859-1883
O’Toole, D. et al. AJCC Cancer Staging System, Version nine: Neuroendocrine Tumors of the Stomach (AJCC, 2023).
Deprez, P. H. et al. Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy Guideline. Endoscopy 54, 412–429 (2022).
pubmed: 35180797
doi: 10.1055/a-1751-5742
Borbath, I. et al. ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors. J. Neuroendocrinol. 34, e13105 (2022). This is a reference paper for standardized and high-quality endoscopic assessment of gNETs which is crucial for proper management of these tumours.
pubmed: 35233848
doi: 10.1111/jne.13105
Rindi, G. et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 449, 395–401 (2006).
pubmed: 16967267
pmcid: 1888719
doi: 10.1007/s00428-006-0250-1
Esposito, G. et al. Narrow band imaging characteristics of gastric polypoid lesions: a single-center prospective pilot study. Eur. J. Gastroenterol. Hepatol. 32, 701–705 (2020).
pubmed: 32356956
doi: 10.1097/MEG.0000000000001697
The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest. Endosc. 58, S3–S43 (2003).
doi: 10.1016/S0016-5107(03)02159-X
Bozkurt, M. F. et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with
pubmed: 28547177
doi: 10.1007/s00259-017-3728-y
Sundin, A. et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology 105, 212–244 (2017).
pubmed: 28355596
doi: 10.1159/000471879
Hope, T. A. et al. SNMMI procedure standard/EANM practice guideline for SSTR PET: imaging neuroendocrine tumors. J. Nucl. Med. 64, 204–210 (2023).
pubmed: 36725249
doi: 10.2967/jnumed.122.264860
Gabriel, M. et al.
pubmed: 17401086
doi: 10.2967/jnumed.106.035667
Srirajaskanthan, R. et al. The role of
pubmed: 20484441
doi: 10.2967/jnumed.109.066134
Skoura, E. et al. The impact of
pubmed: 26471695
doi: 10.2967/jnumed.115.166017
Ambrosini, V. et al.
pubmed: 20107793
doi: 10.1007/s00259-009-1349-9
Putzer, D. et al. Bone metastases in patients with neuroendocrine tumor:
pubmed: 19617343
doi: 10.2967/jnumed.108.060236
Rinzivillo, M. et al. Usefulness of 68-gallium PET in type I gastric neuroendocrine neoplasia: a case series. J. Clin. Med. 11, 1641 (2022).
pubmed: 35329967
pmcid: 8949681
doi: 10.3390/jcm11061641
Laird, A. M. & Libutti, S. K. Management of other gastric and duodenal neuroendocrine tumors. Surg. Oncol. Clin. N. Am. 29, 253–266 (2020).
pubmed: 32151359
doi: 10.1016/j.soc.2019.11.009
Thomas, D. et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur. J. Endocrinol. 168, 185–193 (2013).
pubmed: 23132699
doi: 10.1530/EJE-12-0836
Cavallaro, A. et al. The role of 68-Ga-DOTATOC CT-PET in surgical tactic for gastric neuroendocrine tumors treatment: our experience: a case report. Int. J. Surg. 12, S225–S231 (2014).
pubmed: 24862665
doi: 10.1016/j.ijsu.2014.05.017
Auerbach, M. S., Pisegna, J. R., Kim, S. & Yu, R. Three cases of diffuse, intense stomach uptake on DOTATATE PET. Clin. Nucl. Med. 45, 813–816 (2020).
pubmed: 32604111
doi: 10.1097/RLU.0000000000003153
Hope, T. A. et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J. Nucl. Med. 59, 66–74 (2018).
pubmed: 29025982
pmcid: 6910630
doi: 10.2967/jnumed.117.202275
Hicks, R. J. et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues. Neuroendocrinology 105, 295–309 (2017).
pubmed: 28402980
doi: 10.1159/000475526
Jayasekera, M., Sartin, S. & Bhargava, P. Ga-68 DOTATATE PET/CT in a patient with Zollinger-Ellison syndrome. Radiol. Case Rep. 18, 1046–1048 (2023).
pubmed: 36684643
pmcid: 9849991
doi: 10.1016/j.radcr.2022.12.038
Chan, D. L. et al. Dual [
pubmed: 36434154
doi: 10.1038/s41416-022-02061-5
Chan, D. L. et al. High metabolic tumour volume on 18-fluorodeoxyglucose positron emission tomography predicts poor survival from neuroendocrine neoplasms. Neuroendocrinology 110, 950–958 (2020).
pubmed: 31711058
doi: 10.1159/000504673
Binderup, T., Knigge, U., Loft, A., Federspiel, B. & Kjaer, A.
pubmed: 20103666
doi: 10.1158/1078-0432.CCR-09-1759
Karfis, I. et al. Prognostic value of a three-scale grading system based on combining molecular imaging with
pubmed: 32110279
pmcid: 7021233
doi: 10.18632/oncotarget.27460
Magi, L. et al. Role of [
pubmed: 35149933
pmcid: 9068639
doi: 10.1007/s12020-022-03000-3
Ambrosini, V. et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur. J. Cancer 146, 56–73 (2021). European consensus on the use of SSTR imaging in NEN, including gNENs.
pubmed: 33588146
pmcid: 8903070
doi: 10.1016/j.ejca.2021.01.008
Chung, C.-S. et al. Clinical features and outcomes of gastric neuroendocrine tumors after endoscopic diagnosis and treatment: a Digestive Endoscopy Society of Tawian (DEST) multicenter study. Medicine 97, e12101 (2018).
pubmed: 30235663
pmcid: 6160255
doi: 10.1097/MD.0000000000012101
Ye, H., Yuan, Y., Chen, P. & Zheng, Q. Risk factors for metastasis and survival of patients with T1 gastric neuroendocrine carcinoma treated with endoscopic therapy versus surgical resection. Surg. Endosc. 36, 6162–6169 (2022).
pubmed: 35507062
pmcid: 9283353
doi: 10.1007/s00464-022-09190-1
Merola, E. et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology 95, 207–213 (2012).
pubmed: 21811050
doi: 10.1159/000329043
Uygun, A. et al. Long‐term results of endoscopic resection for type I gastric neuroendocrine tumors. J. Surg. Oncol. 109, 71–74 (2014).
pubmed: 24165913
doi: 10.1002/jso.23477
Kim, H. H. et al. The efficacy of endoscopic submucosal dissection of type I gastric carcinoid tumors compared with conventional endoscopic mucosal resection. Gastroenterol. Res. Pract. 2014, 253860 (2014).
pubmed: 24693280
pmcid: 3947882
doi: 10.1155/2014/253860
Rossi, R. E., Invernizzi, P., Mazzaferro, V. & Massironi, S. Response and relapse rates after treatment with long‐acting somatostatin analogs in multifocal or recurrent type‐1 gastric carcinoids: a systematic review and meta‐analysis. United Eur. Gastroenterol. J. 8, 140–147 (2020).
doi: 10.1177/2050640619890465
Campana, D. et al. Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine 51, 131–139 (2016). Multicentre retrospective study on the clinical and prognostic characterization of type I gNETs.
pubmed: 25814125
doi: 10.1007/s12020-015-0584-z
Sebastian-Valles, F. et al. Chronic treatment with somatostatin analogues in recurrent type 1 gastric neuroendocrine tumors. Biomedicines 11, 872 (2023).
pubmed: 36979851
pmcid: 10045480
doi: 10.3390/biomedicines11030872
Boyce, M. et al. Netazepide, a gastrin/cholecystokinin‐2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. Br. J. Clin. Pharmacol. 83, 466–475 (2017).
pubmed: 27704617
doi: 10.1111/bcp.13146
Fossmark, R. et al. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment. Pharmacol. Ther. 36, 1067–1075 (2012).
pubmed: 23072686
doi: 10.1111/apt.12090
Thakker, R. V. et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab. 97, 2990–3011 (2012).
pubmed: 22723327
doi: 10.1210/jc.2012-1230
Delle Fave, G. et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology 103, 119–124 (2016).
pubmed: 26784901
doi: 10.1159/000443168
Tomassetti, P. et al. Treatment of type II gastric carcinoid tumors with somatostatin analogues. N. Engl. J. Med. 343, 551–554 (2000). Pivotal study showing the effectiveness of somatostatin analogues in the treatment of local unresectable gastrin-dependent type II gNETs.
pubmed: 10954763
doi: 10.1056/NEJM200008243430805
Exarchou, K. et al. Is local excision sufficient in selected grade 1 or 2 type III gastric neuroendocrine neoplasms? Endocrine 74, 421–429 (2021).
pubmed: 34120313
doi: 10.1007/s12020-021-02775-1
Hanna, A. et al. Gastric neuroendocrine tumors: reappraisal of type in predicting outcome. Ann. Surg. Oncol. 28, 8838–8846 (2021).
pubmed: 34120268
doi: 10.1245/s10434-021-10293-7
White, B. E. et al. Incidence and survival of neuroendocrine neoplasia in England 1995-2018: a retrospective, population-based study. Lancet Reg. Health Eur. 23, 100510 (2022).
pubmed: 36176500
pmcid: 9513765
doi: 10.1016/j.lanepe.2022.100510
Yao, J. C. et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387, 968–977 (2016).
pubmed: 26703889
doi: 10.1016/S0140-6736(15)00817-X
de Mestier, L. et al. Treatment outcomes of advanced digestive well-differentiated grade 3 NETs. Endocr. Relat. Cancer 28, 549–561 (2021).
pubmed: 34061764
doi: 10.1530/ERC-21-0109
Rinke, A. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 27, 4656–4663 (2009).
pubmed: 19704057
doi: 10.1200/JCO.2009.22.8510
Pavel, M. et al. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. Eur. J. Cancer 157, 403–414 (2021).
pubmed: 34597974
doi: 10.1016/j.ejca.2021.06.056
Strosberg, J. et al. Phase 3 trial of
pubmed: 28076709
pmcid: 5895095
doi: 10.1056/NEJMoa1607427
Xu, J. et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 21, 1500–1512 (2020).
pubmed: 32966811
doi: 10.1016/S1470-2045(20)30496-4
Zappi, A. et al. Chemotherapy in well differentiated neuroendocrine tumors (NET) G1, G2, and G3: a narrative review. J. Clin. Med. 12, 717 (2023).
pubmed: 36675645
pmcid: 9861419
doi: 10.3390/jcm12020717
Niederle, B. et al. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology 103, 125–138 (2016).
pubmed: 26758972
doi: 10.1159/000443170
Brighi, N. et al. Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study. Dig. Liver Dis. 51, 689–694 (2019).
pubmed: 30314949
doi: 10.1016/j.dld.2018.09.013
Brighi, N. et al. Biliary stone disease in patients with neuroendocrine tumors treated with somatostatin analogs: a multicenter study. Oncologist 25, 259–265 (2020).
pubmed: 32162819
doi: 10.1634/theoncologist.2019-0403
Brabander, T. et al. Long-term efficacy, survival, and safety of [
pubmed: 28428192
doi: 10.1158/1078-0432.CCR-16-2743
Mitjavila, M. et al. Efficacy of [
pubmed: 36877234
pmcid: 10250456
doi: 10.1007/s00259-023-06166-8
Pavel, M. et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 844–860 (2020).
pubmed: 32272208
doi: 10.1016/j.annonc.2020.03.304
Shah, M. H. et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl Compr. Cancer Netw. 19, 839–868 (2021).
doi: 10.6004/jnccn.2021.0032
Ricci, C. et al. Treatment of advanced gastro-entero-pancreatic neuro-endocrine tumors: a systematic review and network meta-analysis of phase III randomized controlled trials. Cancers 13, 358 (2021).
pubmed: 33561087
pmcid: 7835931
doi: 10.3390/cancers13020358
Chan, J. et al. LBA53 Alliance A021602: phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET). Ann. Oncol. 34 (Suppl. 2), S1292 (2023).
doi: 10.1016/j.annonc.2023.10.047
Garcia-Carbonero, R. et al. Advances in the treatment of gastroenteropancreatic neuroendocrine carcinomas: are we moving forward? Endocr. Rev. 44, 724–736 (2023).
pubmed: 36879384
pmcid: 10335166
doi: 10.1210/endrev/bnad006
Sorbye, H. et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. J. Neuroendocrinol. 35, e13249 (2023).
pubmed: 36924180
doi: 10.1111/jne.13249
Lamberti, G. et al. Targeted genomic profiling and chemotherapy outcomes in grade 3 gastro-entero-pancreatic neuroendocrine tumors (G3 GEP-NET). Diagnostics 13, 1595 (2023).
pubmed: 37174986
pmcid: 10178589
doi: 10.3390/diagnostics13091595
Dasari, A., Shen, C., Devabhaktuni, A., Nighot, R. & Sorbye, H. Survival according to primary tumor location, stage, and treatment patterns in locoregional gastroenteropancreatic high-grade neuroendocrine carcinomas. Oncologist 27, 299–306 (2022).
pubmed: 35380711
pmcid: 8982433
doi: 10.1093/oncolo/oyab039
Schmitz, R., Mao, R., Moris, D., Strickler, J. H. & Blazer, D. G. Impact of postoperative chemotherapy on the survival of patients with high-grade gastroenteropancreatic neuroendocrine carcinoma. Ann. Surg. Oncol. 28, 114–120 (2021).
pubmed: 32556871
doi: 10.1245/s10434-020-08730-0
Morizane, C. et al. Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial. JAMA Oncol. 8, 1447–1455 (2022).
pubmed: 35980649
pmcid: 9389440
doi: 10.1001/jamaoncol.2022.3395
McNamara, M. G. et al. NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma. EClinicalMedicine 60, 102015 (2023).
pubmed: 37287870
pmcid: 10242623
doi: 10.1016/j.eclinm.2023.102015
Walter, T. et al. Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial. Lancet Oncol. 24, 297–306 (2023).
pubmed: 36739879
doi: 10.1016/S1470-2045(23)00001-3
Maio, M. et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann. Oncol. 33, 929–938 (2022).
pubmed: 35680043
doi: 10.1016/j.annonc.2022.05.519
Riechelmann, R. P., Taboada, R. G., de Jesus, V. H. F., Iglesia, M. & Trikalinos, N. A. Therapy sequencing in patients with advanced neuroendocrine neoplasms. Am. Soc. Clin. Oncol. Educ. Book. 43, e389278 (2023). ASCO educational book about the challenging management of advanced metastatic NEN, including gNENs.
pubmed: 37257140
doi: 10.1200/EDBK_389278
Subbiah, V. et al. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. Nat. Med. 28, 1640–1645 (2022).
pubmed: 35962206
pmcid: 9388374
doi: 10.1038/s41591-022-01931-y
Sigal, D. S. et al. Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors. Oncotarget 9, 35809–35812 (2018).
pubmed: 30533196
pmcid: 6254675
doi: 10.18632/oncotarget.26260
Doebele, R. C. et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 21, 271–282 (2020).
pubmed: 31838007
doi: 10.1016/S1470-2045(19)30691-6
Hong, D. S. et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 21, 531–540 (2020).
pubmed: 32105622
pmcid: 7497841
doi: 10.1016/S1470-2045(19)30856-3
Idrees, K. et al. Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. J. Surg. Oncol. 117, 284–289 (2018).
pubmed: 28940307
doi: 10.1002/jso.24834
Singh, S. et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J. Glob. Oncol. 3, 43–53 (2017).
pubmed: 28717741
doi: 10.1200/JGO.2015.002980
Gosain, R. et al. Health-related quality of life (HRQoL) in neuroendocrine tumors: a systematic review. Cancers 14, 1428 (2022).
pubmed: 35326587
pmcid: 8946839
doi: 10.3390/cancers14061428
Yadegarfar, G. et al. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br. J. Cancer 108, 301–310 (2013).
pubmed: 23322194
pmcid: 3566824
doi: 10.1038/bjc.2012.560
Strosberg, J. et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with
pubmed: 29878866
pmcid: 6366953
doi: 10.1200/JCO.2018.78.5865
Strosberg, J. R. et al. Symptom diaries of patients with midgut neuroendocrine tumors treated with
pubmed: 33771903
pmcid: 8612179
doi: 10.2967/jnumed.120.258897
Pavel, M. E. et al. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1411–1422 (2017).
pubmed: 28838862
doi: 10.1016/S1470-2045(17)30471-0
Ramage, J. K. et al. Observational study to assess quality of life in patients with pancreatic neuroendocrine tumors receiving treatment with everolimus: the OBLIQUE study (UK phase IV trial). Neuroendocrinology 108, 317–327 (2019).
pubmed: 30699423
doi: 10.1159/000497330
Peipert, B. J., Goswami, S., Yount, S. E. & Sturgeon, C. Health-related quality of life in MEN1 patients compared with other chronic conditions and the United States general population. Surgery 163, 205–211 (2018).
pubmed: 29128174
doi: 10.1016/j.surg.2017.04.030